Search

Your search keyword '"Jore MM"' showing total 42 results

Search Constraints

Start Over You searched for: Author "Jore MM" Remove constraint Author: "Jore MM"
42 results on '"Jore MM"'

Search Results

1. Target-agnostic identification of human antibodies to Plasmodium falciparum sexual forms reveals cross stage recognition of glutamate-rich repeats.

2. A Pfs48/45-based vaccine to block Plasmodium falciparum transmission: phase 1, open-label, clinical trial.

3. Clinical formulation development of Plasmodium falciparum malaria vaccine candidates based on Pfs48/45, Pfs230, and PfCSP.

4. Pfs230 Domain 7 is targeted by a potent malaria transmission-blocking monoclonal antibody.

5. Modeling the Impact of a Highly Potent Plasmodium falciparum Transmission-Blocking Monoclonal Antibody in Areas of Seasonal Malaria Transmission.

6. Potent transmission-blocking monoclonal antibodies from naturally exposed individuals target a conserved epitope on Plasmodium falciparum Pfs230.

7. Highly potent, naturally acquired human monoclonal antibodies against Pfs48/45 block Plasmodium falciparum transmission to mosquitoes.

8. Naturally acquired antibodies to gametocyte antigens are associated with reduced transmission of Plasmodium vivax gametocytes to Anopheles arabiensis mosquitoes.

9. Safety, tolerability, and Plasmodium falciparum transmission-reducing activity of monoclonal antibody TB31F: a single-centre, open-label, first-in-human, dose-escalation, phase 1 trial in healthy malaria-naive adults.

10. Deceiving and escaping complement - the evasive journey of the malaria parasite.

11. Structure of the malaria vaccine candidate Pfs48/45 and its recognition by transmission blocking antibodies.

12. Vaccination with a structure-based stabilized version of malarial antigen Pfs48/45 elicits ultra-potent transmission-blocking antibody responses.

13. Heterologous Expression and Evaluation of Novel Plasmodium falciparum Transmission Blocking Vaccine Candidates.

14. Human antibodies against noncircumsporozoite proteins block Plasmodium falciparum parasite development in hepatocytes.

15. Structure and function of a family of tick-derived complement inhibitors targeting properdin.

16. Preclinical development of a Pfs230-Pfs48/45 chimeric malaria transmission-blocking vaccine.

17. Monoclonal antibodies block transmission of genetically diverse Plasmodium falciparum strains to mosquitoes.

18. A Reproducible and Scalable Process for Manufacturing a Pfs48/45 Based Plasmodium falciparum Transmission-Blocking Vaccine.

19. Antibody Therapy Goes to Insects: Monoclonal Antibodies Can Block Plasmodium Transmission to Mosquitoes.

20. An inhibitor of complement C5 provides structural insights into activation.

21. Immunity against sexual stage Plasmodium falciparum and Plasmodium vivax parasites.

22. Pf s230 and Pf s48/45 Fusion Proteins Elicit Strong Transmission-Blocking Antibody Responses Against Plasmodium falciparum .

23. Naturally acquired immunity against immature Plasmodium falciparum gametocytes.

24. Structural delineation of potent transmission-blocking epitope I on malaria antigen Pfs48/45.

25. Structural basis for recognition of the malaria vaccine candidate Pfs48/45 by a transmission blocking antibody.

26. Expression of full-length Plasmodium falciparum P48/45 in P. berghei blood stages: A method to express and evaluate vaccine antigens.

27. Publisher Correction: Unravelling the immune signature of Plasmodium falciparum transmission-reducing immunity.

28. Unravelling the immune signature of Plasmodium falciparum transmission-reducing immunity.

29. Towards clinical development of a Pfs48/45-based transmission blocking malaria vaccine.

30. Structural basis for therapeutic inhibition of complement C5.

31. Prokaryotic Argonautes - variations on the RNA interference theme.

32. DNA-guided DNA interference by a prokaryotic Argonaute.

33. Native tandem and ion mobility mass spectrometry highlight structural and modular similarities in clustered-regularly-interspaced shot-palindromic-repeats (CRISPR)-associated protein complexes from Escherichia coli and Pseudomonas aeruginosa.

34. CRISPR immunity relies on the consecutive binding and degradation of negatively supercoiled invader DNA by Cascade and Cas3.

35. RNA in defense: CRISPRs protect prokaryotes against mobile genetic elements.

36. The CRISPRs, they are a-changin': how prokaryotes generate adaptive immunity.

37. Structures of the RNA-guided surveillance complex from a bacterial immune system.

38. Interference by clustered regularly interspaced short palindromic repeat (CRISPR) RNA is governed by a seed sequence.

39. Structural basis for CRISPR RNA-guided DNA recognition by Cascade.

40. H-NS-mediated repression of CRISPR-based immunity in Escherichia coli K12 can be relieved by the transcription activator LeuO.

41. CRISPR-based adaptive and heritable immunity in prokaryotes.

42. Small CRISPR RNAs guide antiviral defense in prokaryotes.

Catalog

Books, media, physical & digital resources